# Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

> **NCT06060704** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 33 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Envafolimab
- **DRUG:** Trifluridine/Tipiracil
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06060704
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11
- **Primary completion:** 2025-03
- **Final completion:** 2025-09
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06060704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06060704, "Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06060704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*